life science engineering

Schibano Pharma sets standards in alleviating the omnipresent pathological symptoms that afflict our modern society with the innovative and sustainable solutions found in their pharmaceutical and medical products.

life science engineering

Schibano Pharma sets standards in alleviating the omnipresent pathological symptoms that afflict our modern society with the innovative and sustainable solutions found in their pharmaceutical and medical products.

As a result of reviews by internal and external control entities, our customers benefit from offers and products of the highest quality. You will find our certificates below:

Certificate here

As a result of reviews by internal and external control entities, our customers benefit from offers and products of the highest quality. You will find our certificates below:

PIONEERS IN PHYTOPHARMACOLOGY

bio-revolution

Driven by the synergy of nature and technology, the innovative potential of the bio-revolution will fundamentally change our lives in the coming decades.

Schibano Pharma applies its expertise in life science engineering at the forefront of the bio-revolution with their re-search of cannabinoid and other active phytological substances, to develop the innovative and sustainable solutions found in their pharmaceutical and medical products.

CONTEMPORARY CHALLENGES

omnipresent pathological symptoms

The innovations of the bio-revolution will significantly improve our lives, health and well-being and consequently pro-vide answers to the relevant diseases that challenge civilisation in our digital age.

As a global pioneer in research and development, Schibano combines its knowledge in the field of phytopharmaceuticals with its expertise in national and international regulatory processes.

Through its "innovation-straight-to-market" strategy, it establishes itself as an interpretive authority on future market trends in the sectors health and wellness.

EUDRA GMDP CERTIFIED

highest quality standard

Complete "Seed to Pharma" in-house supply chain in own production facility

EudraGMDP certified for the production of active cannabinoid substances from a phytological source (one of the first companies worldwide)

Instrumental in the initial and current research & development of cannabis genetics for the production of active phar-maceutical ingredients as well as production processes and technologies.

PHYTO-PHARMACEUTICAL COMPANY

evidence

More than 20 years of experience and leadership in national and international regulatory processes for the approval and licensing of active cannabinoid substances

Development, production and distribution of pharmaceutical products and medical cosmetics

Successful “go-to-market” strategies, as both “first mover” and “smart follower”

Self-financed Swiss phytopharmaceutical company (100% subsidiary of Schibano Pharma Group AG)

Ralf Gengenbach – Geschäftsführer gempex GmbH

Ralf Gengenbach – Managing Director gempex GmbH

The production of medicinal cannabis not only requires a deep understanding of good manufacturing practices (GMP) and a willingness to implement them. Above all, it requires knowledge pertaining to products and processes. This is where Schibano Pharma has proven itself to be a highly professional company where quality is a practised tradition.

EUDRA GMDP CERTIFIED

Complete in-house supply chain

Schibano Pharma is one of the first companies in the world to be EudraGMDP certified for the production of phytologi-cally-sourced active cannabinoid substances.

This level of quality is achieved through a complete supply chain in the company's own production facility in Switzerland. Every single step in the production processing of raw materials, active ingredients and medicinal products, including distribution, therefore bears the highest possible certifiable seal of quality. This enables Schibano Pharma to offer absolute premium quality in the development, production and distribution of phytologically-sourced pharmaceutical products and medical cosmetics - all from a single source and "Made in Switzerland”.

FROM SEED TO PHARMA

raw material production

First end-to-end, certified GMP production line for cannabis flowers as medicinal products. In-house development in cooperation with partner companies (drying, trimming, packaging, analytics, quality management & documentation)

In-house developed THC & CBD genetics for the production of active pharmaceutical ingredients and raw materials (cannabis flowers are approved as active ingredients in Germany)

Development of industrial-scale processes for growing, cultivating, harvesting and drying in accordance with GACP guidelines for professional production of phytological raw materials for active pharmaceutical ingredients

Establishment of product-specific and validated analytical methods for cannabis flowers in good laboratory practices (GLP)

FROM SEED TO PHARMA

active ingredient production

First end-to-end, certified GMP production line for CBD and THC active ingredients as API for distribution to pharma-ceutical companies, pharmacies, clinics and research institutes

Development of the first industrial process technologies and methods for active pharmaceutical ingredient production based on cannabinoid raw materials

Narcotics authorisation for THC to be used in the development of pharmaceutical products

Own GLP-certified laboratory for incoming analysis, in-process controls and release analysis

FROM SEED TO PHARMA

pharmaceutical production

End-to-end, certified GMP production lines for oily solutions with ultra-pure active ingredients

Authorisation for the production of medicinal products (excluding blood products) for human and veterinary medicine as well as medicinal products for human use in clinical trials and studies

Authorisation for GID packaging to reduce the analytical workload of pharmacies and pharmaceutical companies

Development of various non-manufactured and finished medicinal products based on active cannabinoid substances in various dosage forms and the corresponding galenic formulations

All packaging takes place in the company's own class D clean rooms; all product stability tests are carried out in-house in accordance with ICH ₂

Own GLP-certified laboratory for incoming analysis, in-process controls and release analysis

apl. Prof. Dr. Simone Graeff-Hönninger – Universität Hohenheim

Prof. Dr. Simone Graeff-Hönninger – University Hohenheim

Schibano Pharma has been a pioneer in the field of medical cannabis cultivation and research for many years. Our coop-eration with Schibano Pharma is an extremely valuable and always highly innovative opportunity to conduct our cut-ting-edge research and scientific studies in a lively exchange of ideas.

An der Spitze der Forschung und Entwicklung

AT THE TOP

Research & Development

Schibano Pharma is a global pioneering research and development laboratory, which combines its knowledge in the field of phytopharmaceuticals with its expertise in national and international regulatory processes and has become an inter-pretive authority for future market trends in health and wellness as a result of its “innovation-straight-to-market” strategy.

Schibano Pharma is instrumental in the initial and current research and development of cannabis genetics, active phar-maceutical ingredients, medicinal products and cannabinoid-based medical cosmetics.

Start of approval of a first finished pharmaceutical product (FPP) in the form of a compound preparation

Start of approval of a first finished pharmaceutical product (FPP) without indication in Europe

Supplier of phytological CBD active ingredient compliant with DAC monograph and Ph. Eur.

Application for two mono-preparations (THC & CBD) for finished pharmaceutical products with indication

Registration of our cannabis extract as a GMP-compliant nutritional supplement in the USA

Co-development of the first approved transdermal cannabis patch (first THC patch in the world) for 5,000 patients in the USA

Design and construction of the largest European CBD cutting production facility in Italy (2017)

Co-development of a valid NIR spectroscopy rapid analytical tool for in-process controls during API production

Reinhold Specht – geschäftsführender Gesellschafter HARTER GmbH

Reinhold Specht – Executive Partner HARTER GmbH

Through the vision and incredibly vast experience of Daniele Schibano, we have been able to steadily optimise HARTER drying technology for medicinal cannabis from prototype to series production and benefit from his network to establish our international business.

SUPPLIER FOR SUSTAINABLE THC AND CBD AS API

api – active pharmaceutical ingredients

Active pharmaceutical ingredients, abbreviated API, are those substances that give rise to the pharmaceutical effect of a medicinal product during its manufacture, either individually or in combination with other active ingredients.

Years of research and continuous development of processes in the field of active pharmaceutical ingredients, enable Schibano Pharma to offer the highest possible quality for the following cannabinoids:

THC API (according to D-100 monograph) > Click here for data sheets
CBD API (according to DAC C-052 monograph) > Click here for data sheets

In addition, we are authorised to produce test samples for clinical trials in various dosage forms, such as hard gelatine capsules (liquid and powder filling) as well as oily solutions in various containers.

Joshua Meerapfel – CEO SWISS1876 N.A LLC

“With proven expertise as a luxury leading, global tobacco company, we are conquering North America through our exclusive partnership with Schibano Pharma Group and launch of our new brand, SWISS1876.

Engineered using only the finest raw materials and technique, this premier line of Swiss CBD is rapidly gaining traction amongst the most respected medical institutions, American elite and cosmeceutical industries. “

THE THRESHOLD WHERE COSMETICS MEET MEDICINE

swisscbd cosmetics

Under the swisscbd label, Schibano Pharma supplies products that meet the highest standards for the cosmetics market. To produce these, Schibano Pharma uses CBD pure substance (>99%), which is manufactured under GMP conditions. The swisscbd drops are manufactured and filled entirely by the in-house supply chain in the company’s own production facility. For the development and production of the cosmetic products, we work together with renowned Swiss compa-nies in order to also ensure that our customers’ demands for Swiss Quality are met. In addition to the swisscbd products already available, Schibano Pharma is currently developing a new dermatological cosmetics line, which will be launched in the fourth quarter.

To the shop

Contact:

info@schibano-pharma.ch
+41 (0)71 360 02 24